-
Whitehawk Therapeutics presents data on PTK7 as cancer drug target
-
Tempus partners with Whitehawk Therapeutics for cancer research
-
Whitehawk Therapeutics, Inc. (WHWK) Misses Q2 EPS by 101c
-
Whitehawk Therapeutics, Inc. (WHWK) Tops Q1 EPS by 218c
-
Whitehawk Therapeutics (WHWK) Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals

